Biogen News

Jeff Auxier's Firm Dissolves Textainer Group Position, Trims Biogen

Yahoo FinanceMay 8 14:01 ET

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Yahoo FinanceMay 8 09:40 ET

Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating

Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ. Price: 218.82, Change: -0.10, Percent Change: -0.05

MT NewswiresMay 8 06:26 ET

Eli Lilly Alzheimer's Therapy Set for June FDA AdCom Meeting

Seeking AlphaMay 7 09:38 ET

Biogen Is Maintained at Buy by HSBC

Biogen Is Maintained at Buy by HSBC

Dow JonesMay 3 14:50 ET

HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating

Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ. Price: 216.17, Change: +2.66, Percent Change: +1.25

MT NewswiresMay 3 12:01 ET

Express News | Biogen Inc : HSBC Raises Target Price to $342 From $339

ReutersMay 3 00:18 ET

Biogen Reports Progress on Corporate Responsibility Priorities

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environmentCAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today a

BiogenMay 2 00:00 ET

AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation

Seeking AlphaMay 1 11:44 ET

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Yahoo FinanceMay 1 09:50 ET

Some Investors May Be Willing To Look Past Biogen's (NASDAQ:BIIB) Soft Earnings

Biogen Inc.'s (NASDAQ:BIIB) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. However, we think the company is showing some signs that things are mor

Simply Wall StMay 1 07:03 ET

The Analyst Landscape: 27 Takes On Biogen

In the preceding three months, 27 analysts have released ratings for Biogen (NASDAQ:BIIB), presenting a wide array of perspectives from bullish to bearish.The following table provides a quick overview

BenzingaApr 29 13:01 ET

Biogen Is Maintained at Outperform by Oppenheimer

Biogen Is Maintained at Outperform by Oppenheimer

Dow JonesApr 29 12:59 ET

Express News | Oppenheimer Maintains Outperform on Biogen, Maintains $270 Price Target

BenzingaApr 29 12:49 ET

Biogen on Pace for Largest Percent Increase Since November 2022 -- Data Talk

Biogen Inc. (BIIB) is currently at $218.61, up $9.71 or 4.65% --Would be highest close since March 21, 2024, when it closed at $220.75 --On pace for largest percent increase since Nov. 30, 2022, whe

Dow JonesApr 29 11:10 ET

Oppenheimer Remains a Buy on Biogen (BIIB)

TipRanksApr 29 07:58 ET

Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceApr 28 09:26 ET

Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Yahoo FinanceApr 27 08:56 ET

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Yahoo FinanceApr 26 08:25 ET

Express News | EMA Says Chmp Adopted Positive Opinions for Tofidence (Tocilizumab)

ReutersApr 26 06:57 ET